Brokerages Set OptimizeRx Corp. (NASDAQ:OPRX) Price Target at $21.00

OptimizeRx Corp. (NASDAQ:OPRX) has earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $21.00.

Several equities research analysts have issued reports on OPRX shares. Wall Street Zen upgraded shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Stephens lowered their price objective on OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Monday, November 17th. Zacks Research lowered shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday, December 22nd. Finally, Citizens Jmp raised their price target on OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th.

OptimizeRx Price Performance

Shares of OptimizeRx stock opened at $10.35 on Friday. The business’s fifty day moving average price is $12.58 and its 200 day moving average price is $15.61. OptimizeRx has a twelve month low of $3.99 and a twelve month high of $22.25. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $192.92 million, a P/E ratio of 27.23 and a beta of 1.18.

Hedge Funds Weigh In On OptimizeRx

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. CenterBook Partners LP bought a new position in OptimizeRx during the third quarter valued at approximately $6,331,000. Manatuck Hill Partners LLC grew its stake in shares of OptimizeRx by 139.5% during the second quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company’s stock valued at $6,142,000 after purchasing an additional 265,000 shares during the last quarter. Kennedy Capital Management LLC grew its holdings in OptimizeRx by 42.8% during the 3rd quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock worth $13,836,000 after acquiring an additional 202,446 shares during the period. Invesco Ltd. acquired a new stake in OptimizeRx during the 3rd quarter worth $4,081,000. Finally, Harvest Investment Services LLC acquired a new stake in shares of OptimizeRx in the 3rd quarter valued at about $3,441,000. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.